News

Ideas That Generate Results

In US alone, patents of biologics worth US$ 67 Billion will expire before 2020. These biologics majorly include the blockbuster drugs of the pharma giants. As these drugs approach their patent expiry, pharma giants are looking for ways to protect their heavily invested upon innovations. One such strategy is patent fencing or patent blocking. Following the same strategy, Roche, has already released Kadcyla, an ADC, based on its blockbuster drug Herceptin for breast cancer. Big pharma players are therefore, using ADCs as an opportunity to fence the patents protecting their blockbuster drugs.
 
According to our report, “Global Antibody Drug Conjugate Market Outlook 2018”, backed by improved understanding and better technology, the ADC market is anticipated to reach US$ 3.45 Billion by 2018. Our report analyzes the market for Adcetris and Kadcyla in detail. Market potential for these drugs has been estimated keeping in mind the fact that these drugs are being tested in clinical trials for various indications apart from the ones for which they are approved.
 
The report also provides an insight into the key ADCs that are currently in pipeline. Apart from new drug candidates, previously approved drugs are also being tested for other indications. Later in the report, strategic activities such as mergers, acquisitions and collaborations that have taken place over ADC have been provided.
 
At the end, major players of ADC market have been discussed. A brief business overview of every player has been provided alongwith their product and pipeline portfolio and recent developments. A comparative strength and weakness analysis of these players has been done. Overall, the report will prove to be a complete source of knowledge and analysis for clients and potential investors.
 
For FREE SAMPLE of this report visit: http://www.rncos.com/Report/IM667.htm
 
Check Related REPORTS on: http://www.rncos.com/Healthcare_Industry.htm